wet age-related macular degeneration

Clearside’s wet AMD drug-device combo shines in Phase IIb study
Clinical Trials Arena
Fri, 10/11/24 - 09:40 am
Clearside Biomedical
clinical trials
wet age-related macular degeneration
CLS-AX
drug-device combos
FDA
4DMT’S Gene Therapy for AMD Clears Phase II, Heads to Late-Stage Studies
BioSpace
Thu, 09/19/24 - 11:07 am
4DMT
gene therapy
AMD
clinical trials
wet age-related macular degeneration
4DMT Unveils More Positive Data for Wet AMD Candidate
BioSpace
Thu, 07/18/24 - 11:29 am
4D Molecular Therapeutics
wet age-related macular degeneration
4D-150
clinical trials
Roche to reintroduce eye implant med Susvimo 2 years after recall
Fierce Pharma
Mon, 07/8/24 - 11:06 pm
Roche
Susvimo
FDA
wet age-related macular degeneration
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
Pharma Voice
Wed, 04/24/24 - 08:42 am
Regenxbio
AbbVie
gene therapy
ABBV-RGX-314
wet age-related macular degeneration
diabetic retinopathy
4DMT gene therapy cuts need for Eylea in wet AMD trial
Pharmaphorum
Mon, 02/5/24 - 10:09 am
4D Molecular Therapeutics
wet age-related macular degeneration
clinical trials
gene therapy
Eylea
EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results
BioSpace
Mon, 12/4/23 - 06:12 pm
Eyepoint
clinical trials
wet age-related macular degeneration
Eylea
EYP-1901
FDA Denies Outlook’s Wet AMD Bid, Issues Complete Response Letter
BioSpace
Wed, 08/30/23 - 11:01 am
Outlook Therapeutics
ONS-5010
wet age-related macular degeneration
FDA
Sandoz plans to enter the Eylea biosimilar race
Clinical Trials Arena
Tue, 08/15/23 - 10:03 am
Sandoz
generics
biosimilars
Eylea
Novartis
wet age-related macular degeneration
Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Clinical Trials Arena
Thu, 07/20/23 - 10:04 am
Roche
Vabysmo
diabetic macular edema
wet age-related macular degeneration
4DMT provides clinical programme updates for its wet AMD gene therapy
Clinical Trials Arena
Tue, 07/18/23 - 11:40 am
4D Molecular Therapeutics
wet age-related macular degeneration
RNAi
4D-150
Ocular Therapeutix gears up for pivotal trial in wet AMD
Clinical Trials Arena
Mon, 06/12/23 - 11:30 pm
Ocular Therapeutix
clinical trials
OTX-TKI
wet age-related macular degeneration
Genentech opens up eye patients’ world with Vabysmo
Medical Marketing and Media
Thu, 04/20/23 - 11:40 pm
Genentech
Vabysmo
wet age-related macular degeneration
DTC ads
Roche issues voluntary recall for Susvimo over manufacturing issue
Endpoints
Sun, 10/23/22 - 06:57 pm
Roche
Medtech
ocular implants
Susvimo
wet age-related macular degeneration
product recalls
A dozen years in the making, a UC Berkeley spinout nabs funds to take on the eye
Endpoints
Wed, 10/5/22 - 10:38 am
UC Berkley
wet age-related macular degeneration
Valitor
Ocular Therapeutix joins the long-acting race
EP Vantage
Wed, 09/28/22 - 10:40 am
Ocular Therapeutix
wet-AMD
wet age-related macular degeneration
OTX-TKI
Bayer, Regeneron's eye drug shown to work at higher dose, longer intervals
Yahoo/Reuters
Thu, 09/8/22 - 04:33 pm
Bayer
Regeneron
Eylea
diabetic macular edema
wet age-related macular degeneration
Microcap's effort to take on Eylea with Avastin biosimilar faces significant FDA roadblock
Endpoints
Tue, 05/31/22 - 10:51 am
Outlook Therapeutics
Avastin
biosimilars
wet age-related macular degeneration
Roche
bevacizumab
Eylea keeps its lead in the retinal space as physicians remain hesitant on Roche's Susvimo — report
Endpoints
Thu, 05/12/22 - 10:44 pm
Roche
Susvimo
wet age-related macular degeneration
physicians
Unity Bio slashes headcount in half to save cash ahead of eye drug readouts
MedCity News
Sat, 02/5/22 - 12:00 pm
Unity Biotechnology
layoffs
diabetic macular edema
wet age-related macular degeneration

Pages